Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
Portfolio Pulse from Vandana Singh
Denali Therapeutics announced new interim results from its Phase 1/2 study of DNL310 IDS in children with MPS II (Hunter syndrome), showing a mean reduction of 64% in serum neurofilament light (NfL), a key biomarker of neurodegeneration. The FDA recently recommended assessing NfL as an exploratory endpoint for aneuronopathic MPS II.
June 20, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics' Phase 1/2 study of DNL310 IDS in children with Hunter syndrome showed a 64% reduction in serum neurofilament light, a key biomarker of neurodegeneration.
The positive interim results from the Phase 1/2 study of DNL310 IDS indicate that the treatment is effective in reducing a key biomarker of neurodegeneration in children with Hunter syndrome. This is likely to have a positive impact on Denali Therapeutics' stock price in the short term, as it demonstrates the potential of the treatment and may attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100